Dienestrol

Dienestrol

SCHEMBL114016

C/C=C(C(=C/C)/c1ccc(O)cc1)\c1ccc(O)cc1.[SiH3]O[SiH3]

nearest known ligand 0.81

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ESR1

The experimentally established mechanism targets of Dienestrol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 known ✓ P03372 7/20 0.81
MAPT P10636 5/20 0.81
HSD17B10 Q99714 4/20 0.81
LMNA P02545 4/20 0.81
MEN1 O00255 3/20 0.81
CYP3A4 P08684 3/20 0.81
ALOX15 P16050 3/20 0.81
KMT2A Q03164 3/20 0.81
HIF1A Q16665 3/20 0.81
NR3C1 P04150 2/20 0.81
TP53 P04637 2/20 0.81
CYP1A2 P05177 2/20 0.81
ADORA3 P0DMS8 2/20 0.81
CYP2D6 P10635 2/20 0.81
CYP2C9 P11712 2/20 0.81
CYP2C19 P33261 2/20 0.81
OPRD1 P41143 2/20 0.81
GAA P10253 1/20 0.81
ALOX12 P18054 1/20 0.81
HTT P42858 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Dienestrol SCHEMBL2896848 0.90 ESR1 (1.00) ESR1MAPTHSD17B10LMNAMEN1
Dienestrol SCHEMBL2896853 0.90 ESR1 (1.00) ESR1MAPTHSD17B10LMNAMEN1
Dienestrol SCHEMBL52170 0.90 ESR1 (1.00) ESR1MAPTHSD17B10LMNAMEN1
Dienestrol SCHEMBL8425094 0.88 ESR1 (0.85) ESR1MAPTHSD17B10LMNAMEN1
Dienestrol SCHEMBL6573104 0.88 ESR1 (0.85) ESR1MAPTHSD17B10LMNAMEN1
Dienestrol SCHEMBL9317394 0.87 ESR1 (0.94) ESR1MAPTHSD17B10LMNAMEN1
Dienestrol SCHEMBL3716190 0.85 ESR1 (0.90) ESR1MAPTHSD17B10LMNAMEN1
SCHEMBL13492676 0.81 MAPT (0.81) ESR1MAPTHSD17B10LMNAMEN1
Dienestrol SCHEMBL8854079 0.80 ESR1 (0.71) ESR1MAPTHSD17B10LMNAMEN1
SCHEMBL15721373 0.80 MAPT (0.71) ESR1MAPTHSD17B10LMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2019076589-A1 HYDROLYSIS-LABILE DIENOLSILYL ETHERS OF ODORANT KETONES OR ODORANT ALDEHYDES HENKEL AG & CO. KGAA (DE) 2019-04-25 WO claimed
EP-1638975-A2 METHOD FOR PREPARING OXYCODONE Boehringer Ingelheim Chemicals, Inc. (US) 2006-03-29 EP claimed
JP-2004502637-A 2004-01-29 JP claimed
US-20020143183-A1 METHOD FOR PREPARING OXYCODONE BOEHRINGER INGELHEIM CHEMICALS, INC. (US) 2002-10-03 US claimed
US-6403798-B2 PRODUCING A DIENOL ORGANOSILYL ETHER AT POSITION 6 OF THE C-RING OF CODEINONE THEREBY FORMING A DIENOL ORGANOSILYL ETHER CONGENER OF CODEINONE, OXIDIZING THE INTERMEDIATE TO FORM 14-HYDROXYCODEINONE, AND HYDROGENATING UNSATURATION BOEHRINGER INGELHEIM CHEMICALS, INC. 2002-06-11 US claimed
US-6262266-B1 REACTING MORPHINAN-6-ONE COMPOUND WITH ORGANOSILYL COMPOUND IN PRESENCE OF STRONG AMINE BASE AND APROTIC SOLVENT BOEHRINGER INGELHEIM CHEMICALS, INC. 2001-07-17 US claimed
US-20010005754-A1 Method for preparing oxycodone CHIU FANG-TING (US) 2001-06-28 US claimed
WO-2001029048-A2 METHOD FOR PREPARING OXYCODONE BOEHRINGER INGELHEIM CHEMICALS, INC. (US) 2001-04-26 WO claimed
WO-2001029047-A2 METHOD FOR PREPARING OXYCODONE BOEHRINGER INGELHEIM CHEMICALS, INC. (US) 2001-04-26 WO claimed
JP-11060587-A None JP disclosed
CN-118290464-A Preparation method of 1, 2-bis (trimethylsiloxy) cyclohexene 杭州鑫富科技有限公司 2024-07-05 CN disclosed
CN-115385837-A Method for preparing astaxanthin through canthaxanthin oxidation 万华化学集团股份有限公司 2022-11-25 CN disclosed
CN-110551069-B Synthesis method of 5-phenylpentanol compound and intermediate thereof 中国科学院上海有机化学研究所 2022-10-04 CN disclosed
CN-114276247-A 1,5-enyne ester chiral compound and synthesis method thereof 华中师范大学 2022-04-05 CN disclosed
US-5416225-A Chemical intermediates SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 1995-05-16 US disclosed
WO-1995012567-A1 TOTAL SYNTHESIS OF TAXOL AND ANALOGUES THEREOF SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 1995-05-11 WO disclosed
WO-1993020036-A1 TOTAL SYNTHESIS OF TAXOL SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 1993-10-14 WO disclosed
US-5250710-A Dihydropyran derivatives, processes for preparation and use RHONE-POULENC NUTRITION ANIMALE (FR) 1993-10-05 US disclosed
US-5157133-A Vitamin A and E precursors RHONE-POULENC NUTRITION ANIMALE (FR) 1992-10-20 US disclosed
US-5126128-A Pheromones JAPAN TOBACCO INC. (JP) 1992-06-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010005754-A1 Method for preparing oxycodone OPRK1, OPRM1, OPRD1 ESR1 3016/4885MAPT 1928/4885HSD17B10 129/4885
US-20020143183-A1 METHOD FOR PREPARING OXYCODONE OPRK1, OPRM1, OPRD1 ESR1 3016/4885MAPT 1928/4885HSD17B10 129/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.